Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients

21 Jul 2021

Abstract excerpt

Lamivudine, also widely known as 3TC belongs to a family of nucleotide/nucleoside analogues of cytidine or cytosine that inhibits the Reverse Transcriptase (RT) of retroviruses such as HIV. Lamivudine is currently indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection or for chronic Hepatitis B (HBV) virus infection associated with evidence of hepatitis B viral replication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34367956
DOI: 10.3389/fonc.2021.664794

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 PatientsPMID 34367956Read ↗

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus InfectionsSemantic proximity Read ↗

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in CancerSemantic proximity Read ↗

Base-Modified Nucleosides as Chemotherapeutic Agents: Past and FutureSemantic proximity Read ↗

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseasesSemantic proximity Read ↗

Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Semantic proximity Read ↗

Dihydroartemisinin inhibits Epstein-Barr virus reactivation and replication targeting lytic proteins: insights for drug repurposingSemantic proximity Read ↗

Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 <i>in vitro</i> : Rationale for a host-acting antiviral treatment strategy for COVID-19Semantic proximity Read ↗

Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2Semantic proximity Read ↗

4’-fluorouridine as a potential COVID-19 oral drug?: a reviewSemantic proximity Read ↗

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.Semantic proximity Read ↗

Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket.Semantic proximity Read ↗

Elucidation of the molecular interactions that enable stable interaction between HIV protease inhibitor ritonavir and human DNA repair enzyme ALKBH2: a molecular dynamics simulation studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.